Novartis AG
Natriuretic peptide receptor 1 antibodies and methods of use
Last updated:
Abstract:
This disclosure relates to anti-Natriuretic Peptide Receptor 1 (NPR1) antibodies including agonist antibodies which are able to activate the NPR1 receptor, pharmaceutical compositions comprising the same, and methods of treatment comprising the same.
Status:
Grant
Type:
Utility
Filling date:
10 Jun 2020
Issue date:
20 Jul 2021